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Abstract: Salmonella is an important genus of Gram-negative pathogens, treatment of which has 
become problematic due to increases in antimicrobial resistance. This is partly attributable to the 
overexpression of tripartite efflux pumps, particularly the constitutively expressed AcrAB-TolC. 
Despite its clinical importance, the structure of the Salmonella AcrB transporter remained unknown 
to-date, with much of our structural understanding coming from the Escherichia coli orthologue. 
Here, by taking advantage of the styrene maleic acid (SMA) technology to isolate membrane 
proteins with closely associated lipids, we report the very first experimental structure of Salmonella 
AcrB transporter. Furthermore, this novel structure provides additional insight into mechanisms of 
drug efflux as it bears the mutation (G288D), originating from a clinical isolate of Salmonella 
Typhimurium presenting an increased resistance to fluoroquinolones. Experimental data are 
complemented by state-of-the-art molecular dynamics (MD) simulations on both the wild type and 
G288D variant of Salmonella AcrB. Together, these reveal several important differences with respect 
to the E. coli protein, providing insights into the role of the G288D mutation in increasing drug efflux 
and extending our understanding of the mechanisms underlying antibiotic resistance. 
Keywords: Salmonella; multidrug efflux pump; membrane proteins; multidrug resistance; AcrB; 
cryo-EM; molecular dynamics; 
 
1. Introduction 
Bacterial multidrug resistance (MDR) is a growing global concern with many antibiotics now 
ineffective against major classes of pathogens. This is especially pertinent in Gram-negative 
organisms, which are intrinsically more resistant due to the presence of a double membrane. 
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Salmonella is an important Gram-negative pathogen, the prevalence of which is increasing especially 
in nosocomial settings. While there are many adaptive routes for the development of MDR in 
Salmonella [1], the role of the multidrug efflux-pumps in the process has been identified as one of the 
key mechanisms for escaping the antibiotic and biocide selective pressures [2–4]. The action of the 
resistance-nodulation-division (RND) transporter AcrB provides the principal antimicrobial 
resistance efflux function in Salmonella enterica serovar Typhimurium (from here on, S. Typhimurium) 
[5]. In vivo AcrB forms a complex with the outer membrane factor (OMF) TolC and the periplasmic 
adaptor protein (PAP) AcrA, forming a functional tripartite complex with a 3:6:3 stoichiometry 
respectively, that spans both the inner and outer membrane [3,6–9]. Among the nine different 
tripartite efflux pumps involved in MDR in S. Typhimurium [5], seven form tripartite complexes with 
TolC [10], and AcrB is the primary transporter associated with MDR. Consistent with its major role, 
the loss of AcrB confers a loss of virulence in Salmonella [11] despite the considerable overlap of 
specificities and partial compensation from overexpression of homologous RND-based tripartite-
pumps [12]. Furthermore, the presence of the AcrAB-TolC efflux pump is required for the 
development of ciprofloxacin resistance [13] and is essential for biofilm formation [14]. 
Most of our current knowledge of AcrB transporter function is based on the E. coli orthologue, 
which shares 94.7% sequence identity to the S. Typhimurium pump. AcrB is organised as a 
homotrimer [15], the functional rotation of which has been proposed as a structural mechanism of 
the efflux process with each protomer undergoing sequential conformational cycling of states known 
as access, binding and extrusion (A, B and E respectively) [16], or, alternatively, in parallel to the 
ATP-synthase cycle—loose, tight, open (L, T, O) [17]. Our understanding of this mechanism has been 
reinforced by both structural and mutagenesis approaches including conditional cross-linking [18–
20], as well as by computer simulations [21,22]. The sequestering of substrates/drugs by the pump 
can occur through a number of different pathways—known as substrate channels, that allow for 
capture of the cargo from the periplasmic space (channel 2 and channel 3) or from the outer leaflet of 
the inner membrane (channel 1 and channel 4) [23–25]. In the L (A) protomer, the channels 1 and 2 
converge on a “proximal” drug-binding pocket (PBP), also known as the “access” pocket [19,23,26], 
which is separated by a “switch-loop” from the deep- or distal-binding pocket (DBP). The latter 
becomes occupied in the T protomer. Channel 3, which originates from an interprotomer space 
known as the vestibule has been shown to bypass the PBP providing direct access to the DBP and a 
distinct selectivity [27]. Channel 4 was discovered very recently as the putative entry path for fusidic 
acid and other carboxylated antibiotics, and is directly connected to the DBP within the T protomer 
(from here on referred as DBPT) [25,28]. 
The electrochemical potential of the membrane is utilised for transport via a proton-relay located 
in the transmembrane (TM) portion of the protein, which induces a conformational change that is 
communicated to the drug binding pockets over > 50 Å via a piston-like action involving TM helix 2 
[21,29]. Recent free energy calculations suggest that protonation of D408 in the TM domain of the 
drug-bound protomer drives the functional rotation [21], albeit all the residues forming the proton 
relay are essential. 
Although the main mechanism of efflux-based resistance in Enterobacteriaceae is provided by 
overexpression of the efflux pumps via mutations of the regulatory regions of their operons or their 
respective repressors (e.g., in E. coli expression of the genes of the principal efflux pump acrAB/tolC 
is predominantly controlled by the interplay of the local and global transcription regulators AcrR and 
MarA, while in Salmonella, these genes are under the control of AcrR and RamA, respectively, for 
reference see [30–32]), a new mechanism of adaptive resistance has been reported, namely the 
selection of mutations altering the specificity of the RND-transporter itself [33]. The particular 
mutation, which arose during the antibiotic treatment of a patient with a complex Salmonella infection 
[34,35], has resulted in a substitution, G288D, within the Salmonella Typhimurium AcrB transporter 
(hereafter STmAcrBG288D). This mutation, is responsible for the occurrence of MDR, particularly to 
ciprofloxacin, increasing the MIC to the drug over 60 folds. Thus, unveiling the molecular structure 
of STmAcrB and the role of specific residues is critical to our understanding of the mechanism of 
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antibiotic recognition and efflux that confers the clinically relevant MDR in Salmonella, yet to date 
there has not been an experimental structure of Salmonella AcrB available. 
Here, we report the first structure of the Salmonella AcrB transporter carrying the clinically 
relevant G288D mutation, solved by cryogenic electron microscopy (cryo-EM). This provides an 
insight into the structural rearrangement AcrB and also the role of the G288D mutation that underlies 
its multidrug resistance. Molecular dynamics (MD) simulations were further employed to provide 
atomistic details on the alteration of protein functional dynamics due to the G288D substitution. 
2. Materials and Methods 
2.1. Cloning of AcrB G288D 
DNA library from clinical isolate strain L18 [33], was used to amplify Salmonella Typhimurium 
AcrB G288D mutant (STmAcrBG288D) using the following primers: 
Salm_acrB+: TAGCTTCATATGCCTAATTTCTTTATCGATCGCCCTATATTTGCGTGGGTG 
Salm_acrB−: ATATTCCTCGAGGCGATGTTCTGTCGAATGACTATGCTCAATATCTTCGC 
The PCR product was cloned into pET26b using the NdeI and XhoI restriction sites (underlined). 
BW25113 was used as the propagating strain for cloning. E. coli C43ΔacrB (DE3) cells were used for 
protein expression. 
2.2. Protein Overexpression and Purification 
The protein was expressed using auto-induction and membrane preparation, styrene maleic acid 
(SMA) solubilisation and protein purification were performed using the protocols previously 
reported [36,37]. Cells were disrupted with a cell disrupter (Constant Systems Ltd.) at 30 kpsi after 
resuspension in 20 mM Tris, 0.5mM EDTA pH 7.9 (4 °C) in a ratio of 4:1 buffer to pellet. The cell 
membranes were isolated by differential centrifugation as previously described [38]. AcrB was 
extracted in its native trimeric form (~340kDa) using 2.5% (w/v) SMA, incubated for 2 h at room 
temperature as previously described [36,39]. The insoluble material was removed by centrifugation 
(100,000× g, 1 h, 4 °C). The supernatant was mixed with 2 mL HisPur™ Cobalt Resin (Thermo 
scientific) and incubated in batch overnight at 4 °C with gentle agitation. Following packing, the resin 
was washed twice with wash buffer (50 mM Tris-HCl, 500 mM NaCl, 10% (w/v) glycerol). After 
elution (50 mM Tris-HCl, 500 mM NaCl, 10% (w/v) glycerol, 300 mM imidazole), the peak fractions 
were pooled out and dialysed against a buffer free of imidazole. 
2.3. Negative Stain Electron Microscopy 
The purified STmAcrBG288D sample was assessed for sample quality by negative stain microscopy 
and grids were prepared as previously described [39]. Briefly, carbon-coated grids were glow-
discharged for 40 s, following which 3µl of the STmAcrBG288D (~20 µg/mL) was added to the grid and 
stained with 2% uranyl acetate. Grids were imaged on a Technai F20 microscope fitted with a field 
emission gun operating at 200kV with a nominal magnification of 50,000× on a CMOS detector. 
2.4. Cryo-Electron Microscopy 
For single particle cryo-EM analysis, gold quantifoil grids (2.1 mesh) were glow discharged (20 
s) before applying 3µL of ~1 mg/mL STmAcrBG288D. Grids were prepared using a Vitrobot Mark IV 
and blotted with Ash-free Whatman filter paper (No. 50) for 6 s using a blot force of 6. Data were 
collected on a G2 Titan Krios fitted with a Gatan K2 direct electron detector operating in counting 
mode at the Astbury Biostructure facility, Leeds, UK. EPU was used to setup a 72-h data collection 
resulting in 3210 micrographs at 1.07 Å/pixel. Motion correction was carried out in MotionCor2 and 
CTF values determined using Gctf [40,41]. Initial two-dimensional (2D) references were generated in 
RELION from manually picked particles to generate reference free classes for autopicking the 
remaining data [42]. Autopicking resulted in a total of 965,863 particles which were subjected to 2D 
classification and after removal of those belonging to poorly resolved classes ~316,000 particles 
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remained. After further rounds of 2D and three-dimensional (3D) classification the particle number 
was reduced to 105,901. The 3D refinement was conducted in RELION 2.1 using a previously 
published cryo-EM AcrB structure (Electron Microscopy Databank (EMD)-3887), filtered to 60 Å as a 
starting model. Following the 3D auto-refinement and particle polishing the resulting model had a 
global resolution of 4.6 Å, as determined by the 0.143 cut-off criteria. The final model had an 
automatically determined B-factor of –305 applied within RELION 2.1 [42]. To examine the effects of 
the G288D mutation on the oligomerization of STmAcrBG288D reconstructions were generated in both 
C1 and C3 symmetry with the C1 symmetry reconstruction reaching a similar resolution and showing 
the same overall architecture. For model fitting the E. coli AcrB crystal structure (Protein databank 
(PDB) ID: 4ZLJ) was put through “threading” in Phyre 2 [43] to produce a model of the STmAcrBWT 
structure. The G288D mutation was manually edited within Coot [44]. The high sequence similarity 
between E. coli AcrB and STmAcrBG288D resulted in a model of high confidence. The resulting 
STmAcrBG288D model was subsequently docked in Chimera followed by rigid body refinement using 
the MDFF program[45]. The model then underwent model refinement in Coot and real space 
refinement in PHENIX. Data collection and refinement statistics are given in Table S1. The 
STmAcrBG288D highest resolution C3 map and fitted structure have been deposited within the Electron 
Microscopy Database (EMDB) with accession number 4460 and 6Z12. 
2.5. Methods for Structural Analysis 
Bioinformatic analysis: Multiple sequence alignments were prepared using MAFFT as 
implemented in MAFFT v.7 server (https://mafft.cbrc.jp/) [46]. ESPript 3.0 was used for structural 
annotations of the alignments [47]. Model superposition and additional visualisation were performed 
in Coot [44] and PyMOL (PyMOL Molecular Graphics System, Version 1.71 Schrödinger, LLC). 
2.6. Homology Modelling 
Three homology models were built of STmAcrBWT and STmAcrBG288D using different X-ray 
crystal structures of wild type AcrB from E. coli (hereafter EcAcrBWT) (PDB IDs 4DX5, 4DX7 [19] and 
2J8S [48]) as templates. The amino acid sequences of both EcAcrBWT and STmAcrBWT were obtained 
from the Uniprot database (Uniprot IDs: P31224 and Q8ZRA7, respectively). The absence of gaps was 
verified through a sequence alignment with ClustalOmega [49]. The homology models were 
generated using Modeller 9.3 [50], each having a MOLPDF score greater than 1.5× 105, and included 
the full range of residues (1–1033) in every template. The homology models of STmAcrBG288D were 
further energy-minimized into the experimental C1 cryo-EM map presented in this work with the 
program  Flex-EM [51]. We performed structural optimization of the models for up to 40 iterations, 
and we ranked the final structures based on their cross-correlation function (hereafter CCF) (see Table 
S2). 
2.7. Molecular Dynamics Simulations 
The homology models of STmAcrBWT and STmAcrBG288D were used as starting structures to 
perform all-atom MD simulations. Following previous work [33,52], we simulated the truncated 
structure including only the porter domain and a few residues at the interface with the TM domain 
(namely, residue segments 32-335 and 564-870), imposing positional restraints on the Cα atoms of the 
residues found within 5 Å from the bottom of the structure (weight of the restraints: 1 kcal/mol). 
Those residues involved were in Subdomain PN1 (V32, A33, Q34, T37, I38, and A39), subdomain PN2 
(A297, N298, A299, T330, P331, and F332), subdomain PC1 (L564, P565, D566, K632, D633, W634, 
P638, G639, E640, A670, I671, V672, T676, A677, and T678) and subdomain PC2 (P710, D711, L712, 
G838, E839, A840, Q865, E866, and R867). The selected portion of the protein was inserted in a 
truncated octahedron filled with 0.15 KCl aqueous solution, setting the minimum distance between 
the protein and the edge of the box to 16 Å. The topology and the initial coordinate files were created 
through the leap module of AMBER18 [53]. Protein and water were represented using the ff14SB force 
field [54] and the TIP3P model [55], respectively, while the parameters for the ions were retrieved 
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from [56]. The system was enclosed in a truncated octahedron filled with 0.15 M KCl aqueous 
solution, and the minimum distance of the protein and the border of the box was set to 16 Å. The MD 
simulations of each system were done according to the following procedure. Firstly, we performed a 
multi-step structural relaxation combining steepest descent and conjugate gradient methods, using 
the pmemd module of AMBER18 [53], as described in previous publications [52,57–59]. The relaxation 
was followed by two MD simulations runs to heat the system from 0 to 310 K: i) from 0 to 100 K in 1 
ns under constant-volume conditions and with harmonic restraints (k = 1 kcal·mol−1·Å−2) on the heavy 
atoms of both the protein and the lipids; ii) from 100 to 310 K in 5 ns under constant pressure (set to 
a value of 1 atm) and with restraints on the heavy atoms of the protein and on the z coordinates of 
the phosphorous atoms of the lipids to allow membrane rearrangement during heating. Next, we 
performed a series of 10 equilibration steps to equilibrate the box dimensions. Each step was of 100 
ps in duration (total 1 ns) and was carried out under isotropic pressure scaling conditions through 
the Berendsen barostat. The Langevin thermostat was also used to maintain the temperature constant, 
with a collision frequency of 1 ps−1. Finally, for every system we performed three independent MD 
simulations, each with a production run of 150 ns in length. Time steps of 0.5 fs and 2 fs were used 
during the heating and equilibration stages, respectively. In the production run a time step of 4 fs 
was adopted under an isothermal-isobaric ensemble after hydrogen mass repartitioning [60]. 
Moreover, the lengths of all the R-H bonds were constrained with the SHAKE algorithm. Coordinates 
were saved every 100 ps. Long-range electrostatic forces were evaluated with the particle mesh Ewald 
(PME) algorithm, with a non-bonded cut-off of 9 Å. 
2.8. Post-Processing of MD Trajectories 
The MD trajectories of STmAcrBWT and STmAcrBG288D were firstly processed by performing a 
cluster analysis with the cpptraj module of AMBER18 [53]. For each trajectory, we considered only 
the last 140 ns of the production run, where the RMSD of the protein with respect to the first frame is 
fairly constant (Figure S1). Every trajectory was subjected to three clustering procedures, in each of 
which the distance-RMSD metric was applied to the DBP of a different monomer of AcrB, generating 
100 clusters. In this way, we obtained 300 clusters per trajectory, divided in three equal subsets (1 
subset per monomer). For each subset, the representative centroid structures of all clusters were used 
to perform several analyses aimed at assessing how the size and shape of the DBP are affected by the 
G288D mutation. To this end, we firstly estimated its volume of in the L, T, and O monomers of both 
STmAcrBWT and STmAcrBG288D. 
The same analysis was then performed on 5 experimentally derived crystal structures of the 
EcAcrBWT, which were chosen as reference structures to identify variations between E. coli and 
STmAcrBWT. These structures have PDB IDs 4DX5, 4DX7 [19], 2J8S [48], 2I6W (the last being a 
symmetric LLL structure) [61] and 6BAJ (the structural model recently derived from cryo-EM data 
by Qiu et al.) [62]. The volume calculations were performed using the POVME 2.0 software [63], 
adopting a grid spacing of 0.5 Å. Additional analyses were conducted to better characterize of the 
impact of the G288D mutation. These included the calculation of the gyration radius of the DBP, the 
number of (pseudo)contacts between the PC1 and PC2 subdomains and the number of waters in the 
first and second solvation shell of residue 288. Such analyses were conducted on every protomer of 
AcrB. Calculations of the radius of gyration and of the number of (pseudo)contacts were carried out 
using in-house tcl scripts and performed on the cluster representatives of STmAcrBWT and 
STmAcrBG288D, as well as on the reference structures of the EcAcrBWT. The radius of gyration was 
computed for three different regions of the DBP: the whole DBP (S46, Q89, S128, E130, E134, F136, 
V139, Q176, L177, F178, S180, E273, N274, D276, Y327, L573, F610, V612, R620, F628), the hydrophobic 
trap (hereafter HP trap)  (F136, V139, F178, Y327, L573, F610, V612, and F628) and the upper DBP 
(S46, Q89, S128, E130, Q176, L177, G179, S180, E273, N274, D276 and R620). As to the number of 
(pseudo)contacts, it was calculated by using a distance cut-off of 10 Å among the Cα carbons of 
selected regions of PC1 (segment 571-667) and PC2 (segments 679-721, 822-859).Regarding the first 
and second water shells of residue 288, these regions were defined using distance cut-offs of 3.4 Å 
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and 5 Å, respectively. Calculations were performed on the last 140 ns of every MD trajectory of 
STmAcrBWT and STmAcrBG288D, using the cpptraj module of AMBER18 [53]. 
Moreover, we monitored the Loose/Tight/Open (LTO) asymmetry of STmAcrBG288D along the 
MD trajectories. To perform this analysis, we used as a reference the EcAcrBWT crystal structure with 
PDB ID 4DX7 [19], in which the protein is found in the LTO state. Thus, for each frame in the last 
140ns of the MD production run, we calculated the RMSD of each conformer of the mutant with 
respect to every conformer of the E. coli reference structure. Only the Cα atoms were considered for 
this calculation. 
3. Results 
3.1. Oligomeric State and Overall Fold of S. Typhimurium AcrB 
Here we report the first ever experimentally-derived structure of the AcrB from S. 
Typhimurium. STmAcrBG288D structure was determined by single particle cryo-EM to a global 
resolution of 4.6 Å. STmAcrBG288D was expressed in an E. coli strain deficient of the native AcrB 
transporter (C43ΔacrB(DE3)) to ensure only the Salmonella orthologue was expressed. For protein 
extraction a styrene maleic acid (SMA) co-polymer approach was used, which we have previously 
shown to be effective at isolating the E. coli AcrB in sufficient levels for both negative-stain and cryo-
EM analysis [36,37,39]. Negative stain and the subsequent cryo-EM sample (Figure 1A) showed a 
mono-disperse sample with no significant aggregation or degradation. 
In contrast to our previous studies of EcAcrB by single particle cryo-EM here we have collected 
significantly more data to improve the resulting resolution and quality of the map [36]. The 
micrographs showed a monodisperse sample with variation in the orientation within the ice (Figure 
1A). The resultant classes revealed clear secondary structure detail for both side and top views 
(Figure 1B). As expected, based on the high sequence similarity, the overall architecture when 
processed in C3 symmetry is similar to that of E. coli AcrB and the functional biological unit of the 
protein is formed by three protomers displaying overall 3-fold symmetry [15] (Figure 1B). The 
transmembrane domain of each protomer is formed by 12 α-helices with a single α-helix flanking the 
base of the transmembrane domain. All the α-helices were well-defined in the cryo-EM map and 
could be placed with high confidence. Although additional density can be seen between the helices 
the resolution is not sufficient to assign any lipids or SMA-polymer with confidence. The periplasmic 
domain is well-resolved and shows features consistent with a local resolution of ~4.1 Å. Both α-helices 
and β-strands are well-resolved and bulky amino acid side-chains can be fitted within the map with 
confidence (Figure 1C). Analysis of the local resolution in C3 map shows the core to be more highly 
resolved with lower resolution features displayed on the exterior of the complex, especially within 
the transmembrane region (Figure 1D). 
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Figure 1. Single particle cryo-electron microscopy reconstruction of STmAcrB G288D processed in C3 
space group. (A) Representative micrograph of STmAcrB G288D collected on a K2 camera, with a 
scale bar in white representing 50 nm. Some representative STmAcrB G288D particles are circled in 
red. (B) Two-dimensional (2D) classes of STmAcrB G288D, produced in RELION as seen from the 
side, high angle, and top views. The scale bar represents 15 nm. (C) Representative experimental 
electron map density processed in C3 space group (mesh), with the refined STmAcrB G288D model 
fitted (cyan). Reference residues labelled within the map include, T44, Y77, N81 and Y819. (D) The C3 
derived map from STmAcrB G288D coloured by local resolution in Angstroms (Å) showing the core 
to be more highly resolved, while the transmembrane flanking regions display lower resolution. 
3.2. Comparison between Salmonella AcrB G288D Processed in the C3 Space Group and the WT E. coli 
Transporters 
The overall structure of STmAcrB is closely related to that of the previously reported E. coli 
orthologue [15], which is consistent with the high level of sequence conservation between the two 
transporters. Sequence analysis reveals a 94.7% identity over the 1048 residues as calculated by the 
SIM Alignment tool (https://web.expasy.org/sim/) [64], (Figure S2). 
The position of the secondary structure elements, and correspondingly the (sub)domain 
organisation is preserved, as is to be expected given there are no significant additional residue inserts 
between the sequences (Figure 2; Figure S2). Consistently, the refined trimer preserves its central 
symmetry, but there are slight discrepancies between the individual protomers which amount to an 
RMSD of 0.35–0.38 Å over the C-alpha backbone. This small change results from each chain being 
fitted and refined within the map without the enforcement of threefold symmetry, reflective of the 
modest (~4.6 Å) resolution within the map. While symmetric structures in the R32 space group have 
been produced both in apo- (1IWG.pdb, [15]), and in a linezolid-bound form of EcAcrB (4K7Q.pdb, 
[65]), as mentioned in the Introduction, in its functional state AcrB presents a breakdown of the central-
axis three-fold symmetry (with conformers referred to as either L, T, O (Loose, Tight, Open) [17]; or 
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A, B, E (Access; Bound; or Extrusion) [16]), which is also observed in the associated X-ray structures. 
The related EcAcrB cryo-EM structure (6CSX.pdb, [62]) also displayed a clear breakdown in the 3-
fold symmetry related to the presence of defined states within the complex. Therefore, we also refined 
STmAcrBG288D in the C1 space group corresponding to an asymmetric trimer resulting in a map which 
closely resembled that of the C3 but with small local changes, consistent with the change in state of 
each protomer (Figure 3). 
 
Figure 2. Comparison of E. coli and S. Typhimurium AcrB three-dimensional (3D) structures. (A). A 
side-view of the trimer of the STmAcrB G288D refined model (cyan) superposed over the E. coli 
orthologue (EcAcrB) (light green) and fitted into the experimental electron density map (semi-
transparent grey). (B–F) Horizontal slices through the STmAcrB C3 cryo-EM electron-density map 
from the top (B) to base (F). Both STmAcrB G288D and EcAcrB are fitted within the density. The 
relative positions of the slices are indicated in (A). The position of G288D mutation within the 
structure is indicated with black arrows in (A) and (D). 
To establish whether the functional rotation states are also preserved in the STmAcrBG288D we set 
out to analyse which of the reported EcAcrB protomer-states our structure resembled most closely. 
Pairwise superpositions using the high-resolution asymmetric structure 4DX7 [19], resulted in a 
RMSD over the STmAcrB backbone in the ranges of 1.69–1.75 to 1.54–1.64 and to 1.51–1.54 Å (against 
the L, T, and O protomers, respectively), while the superposition with the symmetric 4K7Q yielded 
a lower RMSD of 1.03–1.08 Å. Note that superposition of 4K7Q onto 4DX7 chains yielded RMSDs 
corresponding to 1.19, 1.26 and 1.40 Å (for the L, T, and O conformers, respectively). The above 
indicates that the while asymmetric, the conformation observed within our cryo-EM STmAcrB 
structure deviates only moderately from the symmetrised E. coli protomer state. 
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Figure 3. Comparison of STmAcrB G288D cryo-EM maps refined in C3 and C1 with no difference in 
the overall architecture observed but slightly improved resolution in the C3 map. 
3.3. Implications for Drug Selectivity and Efflux Efficiency 
We next sought to understand how sequence differences between the E. coli and S. Typhimurium 
AcrB could translate into differential selectivity to antibiotics. Compared to the EcAcrB, the novel 
STmAcrB structure shows changes in the substrate pathway and the DBP, which is sandwiched 
between the PC1 and PN2 subdomains (Figure 4A) of the periplasmic “pore”- or porter-domain. The 
principal access for soluble drugs from the periplasmic space is via access-tunnel 2, which is located 
between the two principal lobes of the pore-domain, and is connected to the “access” or proximal 
binding pocket (PBP), which also receives the membrane-connected access-tunnel 1 [23]. As 
discussed in the Introduction, the DBP is separated from the PBP by the so-called “Glycine” or 
“switch”-loop, the flexibility of which affects the drug-passage through the latter [19,66]. As will be 
discussed in detail further below, the new STmAcrB structure refined in C1 space group, displays 
asymmetry of protomers, which allows them to be assigned to the specific conformational states (L, 
T, O conformers) described above, however the range of structural variation between them appears 
to be significantly lower than the corresponding conformers within EcAcrB; therefore, we analysed 
the sidechains based on the C3 map, which had a higher local resolution. Due to their high overall 
homology and lack of gaps in the alignment, for ease of presentation, below, when referring to the 
amino-acid differences between the E. coli and Salmonella AcrB, we refer to the divergent residues 
occupying the same position as “substitutions” (see Figure 4B). 
Yet, despite the low overall percentage of sequence difference, the amino-acid differences cluster 
into several discrete groups which may have significant impact on the functional profile of the pump 
and its dynamics. These residue differences can be split into two broad classes based on their 
potential effects—one affecting the conformational dynamics of the protomer, while the second 
impacting the substrate recognition and processing (Figure 4B). 
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Figure 4. (A) General organisation of the STmAcrB G288D trimer and detailed sub-domain 
organisation of the single protomer. (B) Mapping of the sequence differences of STmAcrBG288D vs. 
EcAcrBWT shown on one of the three protomers as red spheres. The labels indicate single-letter residue 
code for the differing residues in E. coli AcrB (in blue), alongside with the equivalent positions and 
substituted side-chains in Salmonella AcrB (in red). The location of the mutation G288D is indicated 
with a yellow box. 
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Of the latter, of particular interest is the M573L substitution in the primary substrate pathway. 
In EcAcrB M573 occupies a critical position between the proximal binding pocket and the switch loop, 
where it is part of a larger Met-cluster that includes M575 and M662; and, in conjunction with the 
F617 which belongs to the switch-loop, also provides a part of the hydrophobic barrier. The residue 
is well resolved in the electron-density map and the Leucine-substitution appears to cause local 
rearrangement of the hydrophobic residues in the so-called hydrophobic trap (HT) of the DBP, 
including a displacement of the ring of F617 (Figure 5A,B). 
A double substitution T714V/S715G located on the outer left rim of the cleft between the two 
lobes of the porter domain, forming the entry of tunnel 2 leading to the proximal drug-binding pocket 
might plausibly impact the selectivity of some drugs. On the opposite rim of the tunnel 2 cleft there 
are two more neighbouring substitutions, namely M649Q plus R653A. While these latter 
substitutions are on the outer rim of the entrance leading to the PBP their nature suggests that they 
would result in a significant rearrangement of the electrostatic properties as well as water-
coordination at the entrance of the pocket and thus may affect drug access (Figure 5C). 
Furthermore, the double substitution L703F/A704G is able to provide a novel phenyl-ring 
stacking interaction with the P718, which could affect the local dynamics of the PBP entry, as these 
residues are located just above V714/G715 and immediately next to R717 which has been shown to 
participate in substrate coordination in the proximal pocket [19,23]. While the quality of the map at 
this region does not permit the unambiguous positioning of F703 its increased bulk must be 
accommodated within the structure (Figure 5C). 
 
Figure 5. Close look of the drug-binding pockets of STmAcrB G288D. (A) The PBP (access binding 
pocket) and the switch loop in STmAcrB G288D with those residues that make up the larger 
hydrophobic “Met-cluster” shown. (B) Representative map density for STmAcrB G288D showing the 
proximity of L573, which in EcAcrB has a bulkier methionine allowing unambiguous placement of 
this sidechain. (C) The outer rim of the cleft between the two lobes of the porter domain which provide 
entry to tunnel 2. (D) Comparison of the structural differences in the DBP in proximity of the G288D 
mutation. In all panels STmAcrB is shown in cyan and EcAcrB in green. 
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3.4. Structural Changes Attributable to G288D Mutation 
An important aspect of our cryo-EM STmAcrB structure refined in a C3 is the presence of a 
G288D mutation which confers greater resistance to fluoroquinolones [33]. However, analysis of the 
novel cryo-EM structure reveals that the G288D mutation brings D288 in close contact with the well-
resolved sidechain of F610. Unfortunately, since negatively charged side-chains are more susceptible 
to radiation damage their resulting density is often poor within the map [67]. Hence, while there is 
no-clear density for D288 side chain, there are also no preferred rotamers that could avoid this close 
contact, suggesting that D288 is either in a less-favoured conformation or maybe in multiple 
conformations between protomers, explaining the poor density for this region. It is interesting to note 
that the β-strand on which G288 is located does not show a significant shift to accommodate the extra 
bulk of aspartate sidechain in the mutated Salmonella structure compared to the EcAcrBWT DBP 
(Figure 5D). However, the residues around D288 show a notable shift, which may accommodate the 
increased bulk and the major change in the electrostatics of the pocket associated with the increased 
hydration detected in our previous work [33]. In particular, F610 is positioned further away from 
position 288 causing an increase in pocket size (Figure 5D). Through these changes the lower part of 
hydrophobic pocket is locally enlarged. This expansion occurs around Q176 and F178, which have 
both previously been shown to participate in the coordination of substrates within AcrB [19,26,33,68]. 
3.5. Mechanism of G288D Mutation Inferred from MD Simulations 
Notably, the above observations were based on the static and medium-resolution cryo-EM 
structure; therefore, we sought to further validate and extend our predictions by performing MD 
simulations starting from several independent homology models. Many different all-atom structural 
models of STmAcrBG288D and STmAcrBWT were derived through homology modelling, and the models 
of the former were minimized against the C1 cryo-EM map presented in this work. Model accuracy 
was evaluated through the CCF (see Materials and Methods), which, for each model, slightly 
improved starting from every template (Table S2). Moreover, the optimization against the cryo-EM 
map did not cause significant structural changes from the initial models (last column in Table S2). 
Starting from these structural models, we performed three independent all-atom MD 
simulations for each system in order to compare structural and dynamical features of the wild type 
and substituted STmAcrB. As described in Materials and Methods, we used a truncated model of 
STmAcrB (largely validated in previous studies; see [69] for a recent review) containing the 
periplasmic portion of the protein only, as it is primarily responsible for drug binding. In fact, despite 
this approximation the asymmetric LTO structure remained well-preserved throughout the MD 
simulations, consistent with the results described previously [33,52]. In particular, cross-RMSD 
calculations between each conformer of our models against each conformer of the reference structure 
(PDB ID 4DX7 [19], see Materials and Methods) revealed that the asymmetric LTO structure is 
similarly retained in STmAcrBG288D (Table 1, below). 
Table 1. Cross-RMSD of each chain of STmAcrBG288D, with respect to every conformer of the EcAcrB 
crystal structure 4DX7. For each model, the calculation was performed on the last 140 ns of the 
production run (see Materials and Methods); the reported values correspond to the average RMSD 
and its standard deviation in the Loose (L), Tight (T) and Open (O) conformer. Only the Cα atoms 
were considered for this calculation. 
Homology Model Chain 
RMSD (Reference Structure: EcAcrB 4DX7) 
L-Conformer T-Conformer O-Conformer 
1 (template: 2J8S) 
A 2.1 (0.1) 2.7 (0.1) 3.2 (0.1) 
B 3.0 (0.1) 2.3 (0.1) 4.1 (0.1) 
C 3.5 (0.1) 3.9 (0.1) 2.2 (0.1) 
2 (template: 4DX5) 
A 2.4 (0.1) 3.1 (0.1) 3.0 (0.1) 
B 3.0 (0.1) 2.2 (0.1) 3.9 (0.1) 
C 3.2 (0.1) 3.9 (0.1) 2.2 (0.1) 
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3 (template: 4DX7) 
A 2.1 (0.1) 2.8 (0.1) 3.4 (0.1) 
B 3.1 (0.1) 2.3 (0.1) 4.1 (0.1) 
C 3.1 (0.1) 3.5 (0.1) 2.1 (0.1) 
We first focused our analysis on the impact of the G288D substitution on the volume of the DPB 
(VDBP) across all AcrB conformers. The largest differences are seen in the volume of the distal binding 
pocket of monomer T (hereafter DBPT), which undergoes a significant expansion with respect to the 
WT Salmonella protein (Table 2). Note that while relative to the E. coli orthologue the VDBP of the 
STmAcrB WT is about 800 Å3 smaller, the effect of G288 mutant on the DBP results in an expansion 
of approximately 450 Å3 in the T-conformer bringing it closer to that of the E. coli orthologue. 
Table 2. Values of the volume of the deep- or distal-binding pocket (DBP) (standard deviations in 
parentheses) in each conformer of AcrB, measured on the E. coli AcrBWT reference structures and on 
the molecular dynamics (MD) trajectories of S. Typhimurium AcrBWT and AcrBG288D (see Materials 
and Methods). 
System 
Volume of DBP [Å3] 
L-Conformer T-Conformer O-Conformer 
EcAcrBWT 1 763 (86) 2315 (76) 1094 (76) 
STmAcrBWT 2 957 (93) 1534 (163) 991 (96) 
STmAcrBG288D 2 807 (78) 1979 (72) 1151 (64) 
1 calculated on experimental reference structures; 2 calculated on representatives of each of the 100 
clusters extracted from the MD trajectories. 
The trend seen for VDBP is confirmed by the calculation of the gyration radius (Table 3), which 
increased significantly only for the DBPT, and in particular in the HP trap, for which the increment 
amounts to almost 1 Å with respect to EcAcrBWT (of less than 0.5 Å in the other monomers). 
Table 3. Radius of gyration of the DBP calculated for every AcrB conformer. The three regions of the 
DBP considered in this calculation are indicated as Whole (entire DBP), Upper (upper part of the 
binding site), and HP trap (hydrophobic trap) (see Materials and Methods for the definition of these 
regions). 
System 
Radius of Gyration [Å] 
L-Conformer T-Conformer O-Conformer 
Whole Upper 
HP 
Trap 
Whole Upper 
HP 
Trap 
Whole Upper 
HP 
Trap 
EcAcrBWT 1 
10.2 
(0.1) 
9.0 
(0.1) 
6.4 
(0.3) 
10.8 
(0.1) 
9.4 
(0.1) 
7.1 
(0.3) 
10.6 
(0.1) 
9.9 
(0.1) 
6.2 
(0.0) 
STmAcrBWT 2 
10.5 
(0.1) 
9.1 
(0.1) 
6.3 
(0.2) 
10.7 
(0.2) 
8.7 
(0.1) 
6.9 
(0.2) 
10.9 
(0.1) 
9.8 
(0.1) 
6.3 
(0.2) 
STmAcrBG288D 
2 
10.5 
(0.1) 
9.2 
(0.1) 
6.4 
(0.1) 
11.2 
(0.1) 
9.2 
(0.2) 
8.0 
(0.2) 
11.0 
(0.1) 
9.9 
(0.1) 
6.5 
(0.2) 
1 calculated on experimental reference structures. 2 calculated on representatives of each of the 100 
clusters extracted from the MD trajectories. 
In addition, the analyses performed on multiple trajectories of both the WT and substituted 
STmAcrB transporter reveal that the number of waters in the 1st and 2nd solvation shells of residue 
288 drastically increases upon mutation (Table 4 and Figure 6, below). The increased hydration of the 
DBPT “breaks” the hydrophobic character of the hydrophobic trap (HP trap), and is likely responsible 
for the increased volume and gyration radius of the DBPT and for the altered specificity of the 
transporter described previously [33]. Our findings are reasonable, as the mutation of a glycine into 
a charged and bulkier residue is expected to have the largest impact on the structure, dynamics, 
hydration of the surrounding (prevalently hydrophobic) region. Moreover, they agree with 
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previously published results [33], although here we have extended the analyses to conformers other 
than T and we have increased confidence by using multiple and independent structural models of 
AcrB. 
Table 4. Number of waters in the first and second solvation shell around residue 288 (in DBP), in 
STmAcrBWT and STmAcrBG288D. The two solvation shells were defined by using a distance cut-off of 
3.4 Å and 5.0 Å, respectively. 
System 
AcrB Conformer 
L-Conformer T-Conformer O-Conformer 
# 1st solv. shell waters 
STmAcrBWT - 0.1 (0.3) 0.0 (0.1) 
STmAcrBG288D - 6.3 (0.6) 3.1 (0.3) 
# 2nd solv. shell waters 
STmAcrBWT 0.0 (0.1) 0.5 (0.4) 0.2 (0.2) 
STmAcrBG288D 0.2 (0.3) 11.3 (1.2) 5.7 (0.5) 
 
Figure 6. Close-up of the residue 288 and surrounding residues of the HP trap in STmAcrBWT and 
STmAcrBG288D. Waters belonging to the first and second hydration shell of residue 288 (distance 
threshold: 5 Å, see Materials and Methods) are also shown, and hydrogen bonds involving residue 
288 are represented as dashed lines. This image has been created using two representative frames of 
MD trajectories. 
Along these lines, in addition to the impact of the mutation on DBPT, we also evaluated here the 
occurrence of structural changes in the other main binding pocket of AcrB, the PBP of the L conformer 
(hereafter PBPL). This site is found beneath the entrance cleft [24] and involves subdomains PC1 and 
PC2. The calculation of the volume of the PBP is less-straightforward due to its relatively open 
architecture and somewhat vague definition of boundaries. Therefore, to quantify the changes 
occurring in the region we evaluated the number of contacts between domains PC1 and PC2, which 
should reflect the opening/closing of the external cleft leading to the access pocket. Indeed, within 
representative E. coli structures, such as 4DX7, the number of average contacts increases from 
monomer L to T and to O. Rather surprisingly we found that these subdomains lose contact in the 
G288D STmAcrB variant compared to the WT protein (Table 5, below), and this especially affects the 
L-conformer. This results in L-conformer being more open towards the periplasm and thus providing 
easier entrance for effluxed compounds. 
Table 5. Number of contacts between the subdomains PC1 and PC2 in the three conformers of AcrB. 
Two residues have been considered in contact if the distance between their Cαs is below 10 Å (see 
Materials and Methods). 
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System 
Number of Contacts (PC1-PC2) 
L-Conformer T-Conformer O-Conformer 
EcAcrBWT 1 9 (5) 10 (2) 38 (2) 
STmAcrBWT 2 12 (4) 6 (2) 38 (7) 
STmAcrBG288D 2 1(1) 7(2) 31 (7) 
1 calculated on experimental reference structures. 2 calculated on representatives of each of the 100 
clusters extracted from the MD trajectories. 
4. Discussion 
Despite its clinical importance, the structure of Salmonella AcrB has remained poorly understood 
until now. This could partially be due to the fact that while the E. coli AcrB readily crystallises and 
has been described as a persistent contaminant of both 2D and 3D crystallization screens even at 
picogram amounts [70,71], the Salmonella transporter proved rather challenging for crystallization via 
traditional approaches, which is unexpected considering the close homology between their 
sequences. This may partially be explained as EcAcrB crystallises in both the H32 or C121 space 
groups and in both these instances the regions which form the crystal contacts differ significantly 
between EcAcrB and STmAcrB. 
To circumvent these issues, here we set-out to employ a cryo-electron microscopy approach to 
the solution of structure of STmAcrB G288D. Furthermore, to minimise structural artefacts we 
decided to pursue the determination of STmAcrB in a native-like membrane environment, by 
utilizing styrene maleic acid (SMA) copolymer [37] for membrane extraction and direct solubilisation 
of the protein from bacterial membranes. The SMA has many benefits over traditional detergents, the 
main one being that it allows for a one-step extraction from cell membrane allowing the retention of 
native structural lipids. We have shown previously the applicability of the SMA-approach, especially 
in relation to AcrB for both negative stain [39] and cryo-EM structure determination [36], the latter 
work reaching sub-9 A ̊ resolution. Optimisation of sample preparation allowed us to push the 
resolution to near 4 Å (in the periplasmic porter domains) of STmAcrB, allowing confident placement 
of most side-chains. Our new STmAcrB structure adds to only a few available recent native-lipid 
membrane structures of RND-transporters including the Acinetobacter baumannii AdeB [72] and 
EcAcrB [62]. 
The transmembrane domain shows a high degree of similarity between the two models with no 
significant changes in helices position that could not be attributed to differences one would expect 
from a lower resolution model. The base of the transmembrane domain shows subtle movement of 
the helices at the base of the membrane (Figure 2E). This helix is clearly resolved within the EM map 
and can be placed with confidence although it is more poorly resolved than the core helices, 
consistent with some degree of mobility of this element, likely due to its position on the periphery of 
the complex. 
On the DBP Pocket and the Effect of G288D 
The resolution of the structures obtained by cryo-EM often does not allow to investigate subtle 
but possibly relevant conformational changes between the WT and G288D variant of STmAcrB, nor 
does it capture the dynamic properties of the respective molecules (and of their dynamic interaction 
with the solvent and the membrane) that ultimately translate into their functional characteristic. 
These dynamic changes, which could be of particular interest at putative binding sites and 
entrance/exit gates for substrates and/or inhibitors, were thus investigated by means of full-atomic 
molecular dynamics simulations. The impact of the G288D substitution was expected to be most 
pronounced for the DBP, where it was predicted to localise. Indeed, several previous high-resolution 
structures of EcAcrB [19,48] demonstrate that G288 sits in the middle of a β-strand beneath F178, a 
residue which is critical for coordination of hydrophobic drugs in the DBP. Moreover, the side chains 
of neighbouring residues point away from the G288D substitution (as seen in Figures 5 and 6), 
suggesting that the side chain of the substituted aspartate residue will protrude into the pocket cavity, 
thus having a major effect on the coordination of potential substrates [33]. 
Microorganisms 2020, 8, 943 16 of 21 
 
The role of mutations within the drug-binding pockets of RND transporters have only recently 
been appreciated as a possible additional mechanism of drug resistance [33,73,74], although earlier 
reports exist [75]. The G288D substitution has been demonstrated to alter the antibiotic resistance 
profiles for clinical isolate of Salmonella, notably increasing resistance to fluoroquinolones. The new 
cryo-EM structure, alongside the computational data presented here sheds further light on the 
possible mechanism of action of G288D substitution. Building on the previous work on the G288D 
[33], here we expanded the scope and the statistical significance of the analysis and moreover, we 
describe the impact of the mutation on all protomers of the transporter by means of additional 
analyses not performed in previous publications. Interestingly, a significant compression of the DBPT 
was seen in STmAcrBWT as compared to the value calculated from the X-ray structures of EcAcrB 
orthologue in the MD simulations. The analysis of our MD simulations suggests that the DBP of 
STmAcrB is significantly less-voluminous than the E. coli orthologue, pointing to an increased steric 
hindrance within the pocket, which might translate into altered substrate-processing kinetics and 
specificities between the two transporters. However, it should be noted that such a compression was 
also seen in previous MD simulations of EcAcrB in the absence of any ligand within the pocket, 
pointing to the possibility of unresolved ligands within the DBPT of these experimental structures 
[58] although further analysis of this feature is beyond the scope the current study. Despite that, the 
MD analysis suggests that DBP of WT STmAcrB exhibits markedly different dynamic properties to 
either the STmAcrB D288G or EcAcrB, both of which show similar, larger volumes in the T-conformer 
(Tables 2 and 3). This may translate into altered specificity and increased efflux of the substrates that 
bind in the DBP. Indeed, changes in the DBP characteristics have been reported to account for the 
discrepancies in the substrate specificity of other RND-transporters e.g., AcrB and AcrD; MexB and 
MexY [26,58,76]. Such effect may be further enhanced by the observed loss of contacts between PC1 
and PC2 of the L-conformer (Table 5), resulting in a conformation of the PBP that is more-open to the 
periplasm and hence more accessible for potential substrates. Thus, the significant DBP and PBP 
rearrangements observed in the structure and in the MD simulations likely account for the 
discrepancies between the WT and G288D variants, and its increased pumping efficiency for 
ciprofloxacin. It is worth noting however, that concurrently to increased fluoroquinolone resistance 
the G288D causes an increased susceptibility to doxorubicin and minocycline [33]. 
While there are still open questions as to the role played by the G288 within the functional cycle 
of AcrB, and so far the G288D mutation is the only mutation affecting this codon resulting in 
multidrug resistance [33], it is notable that mutations at this position have been reported more than 
once, both from Salmonella and E. coli [33,68,77]. The study by Soparkar et al., [68] was searching for 
spontaneous gain-of-function revertants compensating for the critical substitution F610A [78] 
affecting the packing of the hydrophobic trap within the DBP, while the Schuster et al., [77] isolated 
a G288S mutation in response to exposure of cells to the efflux pump inhibitor (EPI) 1-(1-
Naphthylmethyl)-piperazine (NMP), strongly suggesting the residue has an important structural role 
affecting the DBP. Our present data further reinforces the importance of G288, highlighting not only 
changes of the DBP volume and conformation, but also subtle yet tangible conformational 
rearrangements which radiate from the mutation point (Figure 6, Table 4) affecting the packing of 
subdomains PC1 and PC2 and by proxy the proximal binding pocket (PBP). As reported above, these 
might be communicated via different arrangements of the switch-loop [24] and of the loop connecting 
PC2 to the funnel domain, which move closer in STmAcrBG288D compared to STmAcrBWT. Thus, the 
G288D mutation appears to impact the plasticity of the drug-binding pocket and drug-transport 
pathway. These results are further corroborated by the recent analysis of STmAcrBG288D sensitivity to 
another EPI, namely phenylalanine-arginine-β-naphthylamide (PAβN) [79], which not only 
demonstrates that PAβN effectively inhibits both WT and G288D version of the Salmonella AcrB, but 
that that ciprofloxacin and PAβN can stably occupy the DBP at the same time. This implies that PAβN 
potentiates antibiotic activity by restraining drug-binding pocket dynamics, rather than preventing 
antibiotic binding. Hence, further analysis and docking utilising the new structure reported here 
would be invaluable to further elucidate the exact effects of the mutation on the efflux, and inform 
the design of new EPIs. 
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In addition to elucidating the direct effect of G288D mutation, the cryo-EM structure of STmAcrB 
also highlights several important differences in the residues lining the principal drug-entrance tunnel 
2 access leading to the PBP affecting its electrostatics (Figure 4B), as well as identifies a possible role 
for the M573, a residue in the control of coordination of residues at the upper-side of the DBP. Taken 
together these modifications and rearrangements likely account for the subtle differences between 
the specificities and efflux properties of EcAcrB and STmAcrB. 
5. Conclusions 
AcrB is a key transporter contributing to multidrug resistance and recent studies have provided 
significant developments in our understanding of its function. Through the study of different species 
and sequence variants we can start to better understand how these mechanisms are conserved across 
the wider RND-transporter family. 
Increases in MDR in Salmonella Typhimurium are transforming this microorganism into a 
growing health threat globally, which is progressively difficult to treat. Here we have used a single 
particle cryo-EM approach to solve the structure of the STmAcrB G288D mutant derived from a 
clinical isolate strain. Consistent with the high sequence similarity between the STmAcrB and its well-
characterised E. coli orthologue, the structural similarity between the two proteins is high, without 
significant changes in overall architecture. However, there are subtle differences present within the 
structure that could account for the changes in substrate transport. Indeed, computational modelling 
followed by MD-simulations highlighted specific features of the two transporters at their respective 
putative substrate-interaction sites. We also further clarify the effect of G288D mutation on STmAcrB, 
and report that it results in a subtle expansion of the DBP pocket and may thus affect the dynamics 
of the pocket alongside the interprotomer-interactions within the Salmonella AcrB trimer. While the 
significance of the specific substitutions within the DBP of the STmAcrB might require further 
investigation, the availability of the experimental structure of this clinically important protein 
provides the platform to inform future structural analysis and structure-driven design of potential 
novel efflux-pump inhibitors. 
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